64 Results
Sort By:
Published on December 20, 2023
Life is like the changing of seasons, each uniquely beautiful. Just as autumn leaves fall to the ground and make way for winter’s gentle snow, life has transformational cycles. The cycle of life continues through the changing seasons, like how the autumn winds strip the trees of their leaves and…
Published on November 7, 2023
Results of a collaborative study between the Francis Crick Institute, London, and Aalborg University in Copenhagen have shown that there are measurable markers in the blood that can be detected up to eight years before a diagnosis of an inflammatory bowel disease (IBD). The researchers say their findings show that…
Published on October 5, 2023
Sanofi and Teva Pharmaceuticals yesterday announced a collaboration to co-develop and co-commercialize TEV’574, a TL1A inhibitor currently in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn’s disease, two types of inflammatory bowel disease (IBD). The deal is worth potentially $1.5B overall, with $500M upfront. Teva Pharmaceuticals is…
Published on March 30, 2023
A “local” artificial intelligence framework provides more personalized information about how the microbiome influences risk of colorectal cancer, according to a research team from the Tokyo Institute of Technology. Their work separates patients into four distinct subgroups. “Local explanation techniques make it possible to discover the most contributing bacteria for…
Published on March 8, 2023
Mayo Clinic researchers are developing ways to employ artificial intelligence (AI) to increase the detection of potentially cancerous polyps during colonoscopy. The procedure, which remains the standard of care for screening for and preventing colorectal cancer may miss lesions that later lead to more than half of post-colonoscopy cancer cases…
Published on February 21, 2023
The American Gastroenterological Association (AGA) released today new evidence-based guidelines for the use of non-invasive testing methods to identify biomarkers, as a first-line strategy for the monitoring and management of ulcerative colitis (UC) in patients both in remission and with active disease. The updated guidelines, released today in the journal…
Published on December 14, 2022
Clinical-stage biopharma Qu Biologics has announced a collaboration with Sweden’s Karolinska Institute (KI) to characterize the molecular targets of Qu’s Site Specific Immunomodulators (SSIs), an immunotherapy platform designed to restore innate immune function. The research will be led by Prof. Jonas Fuxe, who will become the head of laboratory medicine…
Published on December 12, 2022
A new international research study of progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection has identified a strong link between four genetic variants and nearly a nine-fold increased risk of developing the infection—with one of the variants exhibiting a risk nearly 33 times higher. “It’s critical to…
Published on October 14, 2022
As disease-related data increase, digital twin technology promises to impact precision medicine from clinical trials to clinical care—in silico As healthcare increasingly becomes informed by the analysis—via machine learning and artificial intelligence—of patient-specific, or disease-specific data, a new tool is steadily making its way onto the scene: patient digital twins.…
Published on October 14, 2022
Recent research demonstrating how important the human microbiome is for maintaining good health has led to the founding of many biotech companies hoping to create microbiome-based therapeutics. These five biotech companies all have candidates in clinical trials and are primed to be among the first to receive market approval. The…
Published on December 22, 2021
By the time many couple’s get to the point of an IVF pregnancy, they have already had extensive medical testing and often unpleasant medical procedures, often at a considerable cost. For this reason, prenatal and preimplantation tests to ensure the maximum chance of a healthy pregnancy are popular in this…
Published on December 14, 2021
Pfizer will acquire Arena Pharmaceuticals in a deal worth $6.7 billion to expand its pipeline of immuno-inflammatory disease drugs in development. Etrasimod, Arena’s Phase II/II lead candidate, is an oral, selective sphingosine 1-phosphate (S1P) receptor modulator under study for a range of immuno-inflammatory diseases—notably moderately to severely active ulcerative colitis…
Published on August 31, 2021
Scientists have developed a specialized ‘self-injecting capsule’, which can inject its contents into the stomach wall, that could lead to the development of oral versions of drugs that normally have to be injected. MIT engineers, in collaboration with scientists from Brigham and Women’s Hospital and Novo Nordisk, developed the drug…
Published on March 22, 2021
The co-founders of uBiome face multiple federal charges connected with what prosecutors allege are schemes to defraud health insurance providers and investors in order to raise capital for their now-bankrupt microbiome testing company. Zachary Schulz Apte, 36, and Jessica Sunshine Richman, PhD, 46, were charged Thursday with multiple federal crimes…
Published on August 19, 2020
In a new study, researchers at Rutgers University-Newark have discovered that the gut enzyme lysozyme known to stop bacterial growth in the large intestine of people with ulcerative colitis, instead stimulates inflammation. Their findings were recently published in the journal Immunity in a paper entitled “Paneth Cell-Derived Lysozyme Defines the Composition…